Mustang Bio, Inc. (MBIO)
| Market Cap | 3.20M -64.9% |
| Revenue (ttm) | n/a |
| Net Income | -3.53M |
| EPS | -0.53 |
| Shares Out | 7.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,470 |
| Open | 0.4374 |
| Previous Close | 0.4644 |
| Day's Range | 0.4157 - 0.4469 |
| 52-Week Range | 0.3503 - 1.4300 |
| Beta | 2.20 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 27, 2026 |
About MBIO
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Rα2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an ... [Read more]
Financial Performance
Financial StatementsNews
Mustang Bio Quarterly report: Q3 2026
Mustang Bio has published its Q3 2026 quarterly earnings report on November 5, 2026.
Mustang Bio Quarterly report: Q2 2026
Mustang Bio has published its Q2 2026 quarterly earnings report on August 5, 2026.
MindBio Completes Manufacture and Delivery of First Prototype Edge AI Intoxication and Fatigue Detection Kiosks
VANCOUVER, British Columbia, June 09, 2026 (GLOBE NEWSWIRE) -- MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), (the “Company” or “MindBio”), a biotechnology company commercializi...
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Co...
IBN Announces Latest Episode of The TechMediaWire Podcast featuring Justin Hanka, CEO of MindBio Therapeutics Corp.
This news release has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising This news release has been disseminated on behalf of MindBio Therapeutics Corp. and may...
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication Detection
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Corp...
Mustang Bio Quarterly report: Q1 2026
Mustang Bio has published its Q1 2026 quarterly earnings report on May 5, 2026.
Mustang Bio Annual report: Q4 2025
Mustang Bio has published its Q4 2025 annual report on March 19, 2026.
Mustang Bio Proxy statement: Proxy Filing
Mustang Bio filed a proxy statement on December 3, 2025, providing details for shareholder voting and corporate governance matters.
Mustang Bio Quarterly report: Q3 2025
Mustang Bio has published its Q3 2025 quarterly earnings report on November 7, 2025.
Mustang Bio Quarterly report: Q2 2025
Mustang Bio has published its Q2 2025 quarterly earnings report on August 8, 2025.
Mustang Bio granted orphan drug designation by FDA for MB-101
Mustang Bio (MBIO) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Mustang for MB-101 for the treatment of recurrent diffuse and anaplastic astrocytoma and…
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting ...
Mustang Bio treatment of malignant glioma granted orphan designation
Mustang Bio’s (MBIO) treatment of malignant glioma was granted FDA orphan designation, according to a post to the agency’s website.
Mustang Bio Quarterly report: Q1 2025
Mustang Bio has published its Q1 2025 quarterly earnings report on May 13, 2025.
Mustang Bio regains compliance with Nasdaq requirement
Mustang Bio (MBIO) announced that it has received notice from Nasdaq informing the company that it has regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement as ...
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”)...
Mustang Bio exits lease for Massachusetts facility, divests equipment
Mustang Bio (MBIO) announced the exit of the lease for its manufacturing facility in Worcester, Massachusetts and concurrent divestment of certain fixed assets including furniture and equipment to Abb...
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical break...
Mustang Bio regains compliance with Nasdaq
Mustang Bio (MBIO) announced that it has received notice from Nasdaq informing the company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550…
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
WORCESTER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”...
Mustang Bio Announces Closing of $8 Million Public Offering
WORCESTER, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical bre...
Mustang Bio prices 2.66M shares at $3.01 in public offering
Mustang Bio (MBIO) announced the pricing of a public offering of an aggregate of 2,657,807 shares of its common stock, Series C-1 warrants to purchase up to 2,657,807 shares of…
Mustang Bio Announces Pricing of $8 Million Public Offering
WORCESTER, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical bre...
Mustang Bio Registration statement: Registration Filing
Mustang Bio filed a registration statement on February 5, 2025, providing details about a securities offering with the SEC.